Section 26:2-111.6 - Testing of infants for adrenoleukodystrophy.

NJ Rev Stat § 26:2-111.6 (2019) (N/A)

Copy with citation

Copy as parenthetical citation

26:2-111.6 Testing of infants for adrenoleukodystrophy.

1. a. All infants born in this State shall be tested for adrenoleukodystrophy (ALD) beginning six months following the occurrence of all of the following:

(1) the development of a reliable test or series of tests for screening newborns for ALD using dried blood spots and quality assurance testing methodology for ALD testing;

(2) the availability of quality assurance materials for the ALD test from the federal Centers for Disease Control and Prevention;

(3) the inclusion of newborn screening for ALD in the Recommended Uniform Screening Panel of the United States Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children, after the committee's evidence review of newborn screening for ALD;

(4) the review by the Department of Health of the proposed test; and

(5) the acquisition of equipment necessary to implement the expanded screening tests by the State's Newborn Screening Laboratory.

b. The Department of Health may charge a reasonable fee and any reasonable increase in this fee as necessary, for the test performed pursuant to this section. The amount of the fee and the procedures for collecting the fee shall be determined by the Commissioner of Health.

L.2013, c.90, s.1.

Previous Section

Section 26:2-111.5 - Testing of newborns for certain lysomal storage disorders required.

Next Section

Section 26:2-111.7 - "Let Them Be Little Act," screening of newborns for MPSI and MPSII provided.